Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer

To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability-high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/β-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/β-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion.Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730-49. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663.

Benjamin J. Raphael | Matteo Pellegrini | Ming Yu | Mark D. M. Leiserson | Wei Sun | Colin C Pritchard | Stephen J Salipante | Li Hsu | Reiko Nishihara | Shuji Ogino | Levi A Garraway | Xinmeng Jasmine Mu | Antoni Ribas | Alexander Upfill-Brown | Thomas J Hudson | Charles Connolly | Jeroen R Huyghe | Ulrike Peters | Jennifer Tsoi | Eric S Lander | Daniel K. Wells | Janet L Stanford | David A Wheeler | Zhi Rong Qian | Cristina Puig-Saus | Brian Shirts | Eve Shinbrot | S. Gabriel | E. Lander | T. Hudson | D. Wheeler | L. Garraway | X. Mu | M. Pellegrini | J. Stanford | Catherine J. Wu | Wei Sun | A. Ribas | U. Peters | S. Ogino | R. Nishihara | Z. Qian | C. Fuchs | E. Shinbrot | L. Hsu | S. Shukla | Helena Escuin-Ordinas | S. Hu-Lieskovan | C. Pritchard | S. Salipante | T. Morikawa | J. Huyghe | W. Grady | A. Upfill-Brown | B. Shirts | M. Quist | C. Grasso | Tsuyoshi Hamada | J. Nowak | K. Nosho | M. Geybels | J. Zaretsky | J. Tsoi | D. Shin | C. Puig-Saus | Dennis J. Montoya | M. Giannakis | William M Grady | Charles S Fuchs | Daniel K Wells | Catherine S Grasso | Marios Giannakis | Tsuyoshi Hamada | Michael Quist | Jonathan A Nowak | Kentaro Inamura | Teppei Morikawa | Katsuhiko Nosho | Gabriel Abril-Rodriguez | Helena Escuin-Ordinas | Milan S Geybels | Siwen Hu-Lieskovan | Yeon Joo Kim | Paige Krystofinski | Mark D M Leiserson | Dennis J Montoya | Brian B Nadel | Elleanor H Quist | Ben J Raphael | Daniel Sanghoon Shin | Sachet Shukla | Catherine J Wu | Syed H Zaidi | Jesse M Zaretsky | Stacey B Gabriel | Ming Yu | C. Connolly | Alexander M. Upfill-Brown | Paige Krystofinski | B. Nadel | Gabriel Abril-Rodriguez | K. Inamura | S. H. Zaidi | S. Zaidi | M. Yu | Reiko Nishihara | Teppei Morikawa

[1]  G. Attard,et al.  Prostate cancers that 'Wnt' respond to abiraterone. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Guoping Cai,et al.  Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. , 2017, Cancer discovery.

[3]  T. Ideker,et al.  MHC-I Genotype Restricts the Oncogenic Mutational Landscape , 2017, Cell.

[4]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[5]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[6]  N. Chaput,et al.  Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. , 2017, European journal of cancer.

[7]  Gad Getz,et al.  Analysis of somatic microsatellite indels identifies driver events in human tumors , 2017, Nature Biotechnology.

[8]  Harini Veeraraghavan,et al.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.

[9]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[10]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[11]  S. Garattini,et al.  Immunotherapy for colorectal cancer: where are we heading? , 2017, Expert opinion on biological therapy.

[12]  T. Furuhata,et al.  Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon. , 2017, Anticancer research.

[13]  C. Petraki,et al.  Assessing the clinical utility of Wnt pathway markers in colorectal cancer. , 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[14]  J. Guinney,et al.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.

[15]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[16]  P. Wang,et al.  E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63-linked ubiquitination of TBK1 , 2016, Nature Immunology.

[17]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[18]  Laura M. Heiser,et al.  FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer , 2016, Proceedings of the National Academy of Sciences.

[19]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[20]  H. Ahlfors,et al.  The RNA-Binding Proteins Zfp36l1 and Zfp36l2 Enforce the Thymic β-Selection Checkpoint by Limiting DNA Damage Response Signaling and Cell Cycle Progression , 2016, The Journal of Immunology.

[21]  A. Cerwenka,et al.  CD2–CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection , 2016, European journal of immunology.

[22]  B. Leggett,et al.  RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis , 2016, Oncotarget.

[23]  Xudong Wang,et al.  Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer , 2016, Oncotarget.

[24]  A. Børresen-Dale,et al.  Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer , 2016, Cell reports.

[25]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[26]  Cheng Huang,et al.  NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway. , 2016, Cancer letters.

[27]  Xiaomo Jiang,et al.  Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer , 2016, Cancers.

[28]  M. Shipp,et al.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer , 2016, Proceedings of the National Academy of Sciences.

[29]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[30]  S. Gabriel,et al.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.

[31]  M. Razzaque,et al.  TGIF function in oncogenic Wnt signaling. , 2016, Biochimica et biophysica acta.

[32]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[33]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[34]  Charles Y. Lin,et al.  Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer , 2016, Genome Biology.

[35]  P. McCrea,et al.  Beyond β-catenin: prospects for a larger catenin network in the nucleus , 2015, Nature Reviews Molecular Cell Biology.

[36]  Jun Wang,et al.  Predicting tumor purity from methylation microarray data , 2015, Bioinform..

[37]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[38]  T. Chan,et al.  Cancer Neoantigens and Applications for Immunotherapy , 2015, Clinical Cancer Research.

[39]  A. Ribas.  Releasing the Brakes on Cancer Immunotherapy. , 2015, The New England journal of medicine.

[40]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[41]  Andrei L. Turinsky,et al.  The missing indels: an estimate of indel variation in a human genome and analysis of factors that impede detection , 2015, Nucleic acids research.

[42]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[43]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[44]  Nicholas J. Wang,et al.  Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.

[45]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[46]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[47]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[48]  W. Reith,et al.  NLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module , 2015, PLoS genetics.

[49]  L. Borsu,et al.  AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants , 2015, Molecular Cancer Research.

[50]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[51]  C. Langner.  Serrated and Non-Serrated Precursor Lesions of Colorectal Cancer , 2014, Digestive Diseases.

[52]  M. Kloor,et al.  Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression , 2014, Clinical Cancer Research.

[53]  Kristian Cibulskis,et al.  RNF43 is frequently mutated in colorectal and endometrial cancers , 2014, Nature Genetics.

[54]  Ming Yu,et al.  Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer , 2014, Nature Communications.

[55]  Colin C Pritchard,et al.  Microsatellite instability detection by next generation sequencing. , 2014, Clinical chemistry.

[56]  Reiko Nishihara,et al.  Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review , 2014, Molecular Cancer.

[57]  D. Green,et al.  Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-κB and MAPK signaling , 2014, Proceedings of the National Academy of Sciences.

[58]  J. Hong,et al.  Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer , 2014, Cell Death and Disease.

[59]  J. Wu,et al.  CD58, a novel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer , 2014, Oncogene.

[60]  T. Handel,et al.  Lymphatic Specific Disruption in the Fine Structure of Heparan Sulfate Inhibits Dendritic Cell Traffic and Functional T Cell Responses in the Lymph Node , 2014, The Journal of Immunology.

[61]  Helmut Blum,et al.  Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling , 2014, BMC Genomics.

[62]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[63]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[64]  Yan Wang,et al.  Zinc finger protein ZBTB20 promotes toll-like receptor-triggered innate immune responses by repressing IκBα gene transcription , 2013, Proceedings of the National Academy of Sciences.

[65]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[66]  Simon G. Coetzee,et al.  Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. , 2013, Gastroenterology.

[67]  J. Castle,et al.  HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.

[68]  Koichi S. Kobayashi,et al.  NLRC5: a key regulator of MHC class I-dependent immune responses , 2012, Nature Reviews Immunology.

[69]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[70]  Melanie A. Huntley,et al.  Recurrent R-spondin fusions in colon cancer , 2012, Nature.

[71]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[72]  Amy Li,et al.  NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression , 2012, The Journal of Immunology.

[73]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[74]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[75]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[76]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[77]  P. Laird,et al.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer. , 2012, Genome research.

[78]  Govind Bhagat,et al.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.

[79]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[80]  Laura J. Norton,et al.  Impaired B Cell Development in the Absence of Krüppel-like Factor 3 , 2011, The Journal of Immunology.

[81]  P. Jedlicka,et al.  Ets2 Regulates Colonic Stem Cells and Sensitivity to Tumorigenesis , 2011, Stem cells.

[82]  Shuji Ogino,et al.  Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.

[83]  M. Kloor,et al.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes , 2010, International journal of cancer.

[84]  D. Iliopoulos,et al.  NLR family member NLRC5 is a transcriptional regulator of MHC class I genes , 2010, Proceedings of the National Academy of Sciences.

[85]  Shuji Ogino,et al.  Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. , 2010, The Journal of molecular diagnostics : JMD.

[86]  Mari Mino-Kenudson,et al.  Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype , 2009, Clinical Cancer Research.

[87]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[88]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[89]  John Quackenbush,et al.  Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample , 2008, PloS one.

[90]  R. Rosin-Arbesfeld,et al.  A novel functional screen in human cells identifies MOCA as a negative regulator of Wnt signaling. , 2008, Molecular biology of the cell.

[91]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[92]  D. Morton,et al.  Reorganisation of Wnt-response pathways in colorectal tumorigenesis , 2008, British Journal of Cancer.

[93]  J. Meyerhardt,et al.  Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. , 2007, Neoplasia.

[94]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[95]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[96]  Yusuke Nakamura,et al.  Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis. , 2002, Cancer research.

[97]  R. Copley,et al.  HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient. , 2002, Developmental cell.

[98]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[99]  S. Ferrone,et al.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.